Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone in malignant lymphoma.

R A Gams, J Steinberg, L Posner

    Seminars in Oncology
    |September 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Mitoxantrone shows activity in refractory malignant lymphoma. A higher dose of 14 mg/m2 every 3 weeks yielded better response rates with minimal side effects compared to weekly lower doses.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Quality of life in patients with progressive keratoconus treated with corneal collagen crosslinking.

    International ophthalmology·2025
    Same author

    [Uncommon treatment options for epithelial ingrowth after laser lenticule extraction].

    Die Ophthalmologie·2023
    Same author

    "But not the music": psychopathic traits and difficulties recognising and resonating with the emotion in music.

    Cognition & emotion·2023
    Same author

    Substance use patterns in 9-10 year olds: Baseline findings from the adolescent brain cognitive development (ABCD) study.

    Drug and alcohol dependence·2021
    Same author

    [Successful refractive surgical treatment of a patient with keratoconus using phakic intraocular lenses].

    Die Ophthalmologie·2021
    Same author

    Baseline brain function in the preadolescents of the ABCD Study.

    Nature neuroscience·2021
    Same journal

    A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

    Seminars in oncology·2026
    Same journal

    Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

    Seminars in oncology·2026
    Same journal

    PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

    Seminars in oncology·2026
    Same journal

    Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

    Seminars in oncology·2026
    Same journal

    Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

    Seminars in oncology·2026
    Same journal

    Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

    Seminars in oncology·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Refractory malignant lymphoma presents a significant treatment challenge.
    • Mitoxantrone is an anthracenedione antineoplastic agent with known activity in various cancers.

    Purpose of the Study:

    • To evaluate the efficacy and safety of mitoxantrone in patients with refractory malignant lymphoma.
    • To compare two different dosing regimens of mitoxantrone.

    Main Methods:

    • Two Phase II clinical trials were conducted.
    • Trial 1: Mitoxantrone 5 mg/m2 weekly for 6 weeks (SECSG).
    • Trial 2: Mitoxantrone 14 mg/m2 every 3 weeks (multicenter).

    Main Results:

    • The weekly regimen showed limited efficacy with 4 partial responses and no complete responses.

    Related Experiment Videos

  • The every-3-weeks regimen resulted in 15 responses (2 complete, 13 partial) with minimal toxicity.
  • Side effects in the higher dose arm included mild nausea, vomiting, and alopecia.

    • Conclusions:

    • Mitoxantrone demonstrates significant activity in refractory malignant lymphoma.
    • A higher dose of 14 mg/m2 every 3 weeks appears more effective than a weekly lower dose.
    • Further Phase III trials should consider dose optimization for mitoxantrone.